Søsterhjemmet, Kirkeveien 166, 2.etasje (map)
Yearly, the Norwegian Cancer Society yields grants to cancer research, this year 15 projects divided into three categories: “more knowledge”, “better treatment”, and “a life with and after cancer”.
Fridtjof Lund-Johansen received a grant of 5,33 million NOK from the Norwegian Cancer Society to identify cancer-specific peptides to find better treatments for cancer patients.
JCIT partner Fridtjof Lund-Johansen fikk sammen med 10 andre norske proteomikk-forskere tilslag fra Norges Forskningsråd på en søknad om 100 millioner til massespektrometriutstyr. Massespektrometri er bl.a. helt sentralt for å kartlegge molekyler som kan være mål for immunterapi mot kreft, og JCIT har en stor satsning innen dette området.
Med støtte fra Radiumhospitalets Legat har Karl-Johan Malmberg gjennomført et forskningsopphold ved UCSD i USA. Se intervju nedenfor.
In collaboration with UiO FOCIS CoE, K.G. Jebsen Centre for Cancer Immunology is hosting a symposium with Visiting Professor Peter Parham from Stanford University, USA, and Erik Dissen from the University of Oslo.
Johanna Olweus, Head of Dept of Cancer Immunology at the Institute for Cancer Research, OUS Radiumhospitalet, and Professor at the University of Oslo, was May 21st elected member of the executive board of CIMT during the CIMT 2019 conference in Mainz, Germany.
The Olweus group obtained grant from the BIOTEK 2021 programme at the Research Council of Norway for the project "Treating lymphoma with novel immunotherapy".
The Knut and Alice Wallenberg Foundation has awarded a total of SEK 640 million to 22 research projects in the fields of medicine, science and technology that are considered to offer potential for future scientific breakthroughs.
Dagens Medisin highlights mapping of the human genome and cancer immunotherapy as among the greatest medical breakthroughs since 1998 in an article series looking at the medical advances the last 20 years.
Jodie Goodridge and Karl-Johan Malmberg have received a grant from The Research Council of Norway (RCN) Toppforsk for the project "Programming natural killer cell function through the organelle communication". Their application was among the 16% that was granted.
Senterleder Johanna Olweus i intervju med Aftenposten Vitenskap om sitt arbeid innenfor immunterapi.
Karl-Johan Malmberg has received funding from The Norwegian Cancer Society of 8,95 mill. NOK.
The research group of Johanna Olweus, together with Kite Pharma, will further develop breakthrough technology on immunotherapy against cancer.
The conference explores possibilities for how to create a leading Nordic Life Science hub for research, education, innovation and business focusing this year on health.
Every year The Norwegian Cancer Society supports cancer Research. In 2016 a total of 40 million NOK was granted to immunotherapy.
In connection with American Society of Clinical Oncology (ASCO) naming immunotherapy as the Society’s advance of the year, Professor Johanna Olweus and Professor Karl-Johan Malmberg was interviewed by Dagens Medisin, April 12th 2017.
Malmberg Lab enter into partnership with Fate Therapeutics Inc. to develop off-the-shelf NK cell therapy
Professor and co-Director of K.G. Jebsen Centre of Immunotherapy Karl-Johan Malmberg speaks on "Harnessing Natural Killer Cells in Cancer Immunotherapy" during STREAM mini-symposium.
JCIT Director Professor Johanna Olweus was invited to present immunotherapy, current strategies and comment on K.G. Jebsen Centre’s current work.
Oslo University Hospital gives prizes to six outstanding research articles with key authors from the hospital every six months.
Researchers from the KG Jebsen Centres for Cancer Immunotherapy (JCIT) and Inflammation Research (JIRC) collaborate to develop tomorrow's tools for protein analysis.